Ann: Zantrene highly effective in EMD AML Mouse Model, page-32

Aside from the very promising results did anyone else happen to pick up on the fact that Zantrene was administered using IV through the tail vein during this pre-clinical study? This for me is the first real demonstration of just how far RAC have progressed with it reformulation work.

"The mice were dosed for 5 days every week for three weeks with decitabine at 0.5mg/kg intraperitoneally (IP). Zantrene was dosed weekly using a dose escalation strategy on Days 3 and 5 at 5mg/kg IP (Week 1) or 10mg/kg intravenously (IV) (Weeks 2 & 3; formulated using a solubilisation vehicle)."